Yaz Trial Postponed for Settlement Talks
The first Yaz trial, which was set to begin in January 2012, was postponed in an effort to reach a settlement of the claims. U.S. District Court Judge David Herndon appointed a mediator to work with the parties to reach a settlement. There have been more than 10,000 suits filed in the multi-district Litigation.
Yaz is a combination birth control pill containing drospirenone and ehtinyl estradiol. It is prescribed not only for birth control, but also for symptoms of PMDD, premenstrual dysphoric disorder and even moderate acne. Unfortunately many serious side effects have been alleged as a result of taking Yaz including:
- Heart attacks and strokes
- Deep vein thrombosis (DVT)
- Pulmonary embolisms
- Gallbladder problems
Studies recently published in the British Medical Journal have found that women taking birth control with the hormone drospirenone (which includes Yaz and Yasmin) have a three-fold risk of developing serious blood clots than women taking other types of birth control.
There are more than 25,000 cases pending in U.S. state and federal courts.
If you would like additional information regarding Yaz or Yasmin, please contact us at 622-3344.
HUNDREDS OF NUVARING LAWSUITS PENDING
To date, approximately 1,000 NuvaRing lawsuits have been filed in state and federal courts. Approximately 820 of these are or will be pending in the NuvaRing lawsuit multidistrict litigation (MDL) in the U.S. District Court for the Eastern District of Missouri before Judge Rodney Sippel. Showard Law Firm is filing NuvaRing claims for Arizona residents directly in the MDL.
NuvaRing is a small flexible vaginal ring that is designed to be inserted into the vagina once a month. It is kept in place for three weeks, releasing controlled amounts of ethinyl estradiol (EE) and etonogestrel, which modify female hormones to prevent pregnancy. Etonogestral, also known as “third generation” progestin desogestrel, has been linked to serious health concerns.
In February 2007, the consumer advocacy group Public Citizen petitioned the FDA to ban oral birth control pills that contain third generation progestin desogestrel, since it could double the risk of blood clots when compared to second generation oral contraceptives.
NuvaRing was introduced in 2001 by Organon Pharmaceuticals. A number of otherwise healthy young women on the birth control ring have suffered severe and potentially life threatening injuries such as:
- Pulmonary embolism
- Deep vein thrombosis (DVT)
- Other blood clots
- Stroke or heart attack
- Sudden death
Keep updated on the FDA-funded study that evaluated the risk of blood clots in users of birth control pills containing drospirenone including Yaz (generics Gianvi and Loryna), Yasmin (generics Ocella, Syeda and Zarah), Beyaz and Safyral. Read more here.
Trademark Notice: The use of the name of any product is strictly for identification purposes in attorney advertising. Showard Law Firm is in no way affiliated with the manufacturer of any product referenced on this site.
The Latest News on Defective Contraceptives
- Yaz Update from Bayer stockholder’s newsletter
- Bayer settles some Yasmin lawsuits for $402 million
- FDA wants blood clotting data added to Yaz, Yasmin, others
- Pfizer Recalls 1M Packets of Birth Control Pills
- BREAKING NEWS- YAZ Settlement Discussions to Begin
- FDA Panel: Newer birth control medications should carry stronger safety warnings.
- FDA Questions Safety of newer birth control drugs